About
Oncology and Immunocompromised Patient IPC
Programme Introduction
About this programme
Oncology & Immunocompromised Patient Infection Prevention & Control (IPC) focuses on preventing infections in patients with cancer or other immunocompromising conditions. These patients are highly vulnerable to healthcare-associated infections (HAIs) due to chemotherapy, radiation therapy, immunosuppressive medications, invasive procedures, and prolonged hospital stays. Effective IPC practices are critical to reduce morbidity, mortality, and treatment-related complications.
Oncology and immunocompromised patients face elevated and atypical infection risk — driven by neutropenia, treatment-induced mucosal damage, and the need for repeated invasive interventions.
This programme covers IPC tailored to oncology and immunocompromised care — covering protective environments, neutropenic precautions, device care and outbreak preparedness.
🛡 Built for safer care. Structured, evidence-based, and mapped to global IPC standards — designed to translate directly into stronger patient and staff safety.
Learning objectives
Learning Objectives
What you will achieve
By the end of this programme, learners will have built core IPC competencies directly applicable to clinical practice — translating into safer patient care, stronger compliance, and a more vigilant healthcare environment.
Each outcome below targets a specific dimension of oncology IPC — building the protective infrastructure required for patients whose immune defences are compromised.
By the end of this programme, learners will be able to:
01
Understand infection risks in oncology and immunocompromised patients
02
Apply IPC measures tailored for immunosuppressed patients
03
Prevent device- and procedure-related infections
04
Maintain safe patient environments and handle high-risk procedures
05
Detect early signs of infection and respond promptly
06
Support antimicrobial stewardship in oncology care
07
Ensure compliance with regulatory and accreditation standards
08
Promote continuous quality improvement in infection prevention for immunocompromised patients
Protective environment. Vigilant care. Safer treatment.
Build clinical confidence in infection prevention, one practice at a time.
Who can enroll
Target Audience
Who can enroll
This programme is designed for healthcare professionals across clinical and support roles who play a part in preventing infection and protecting patient and staff safety.
This programme is built for oncology nurses, haematologists, infectious disease specialists, infection preventionists and clinical leaders in cancer care and immunocompromised settings.
Designed for these professionals
🧑⚕️
01
Oncology nurses and ward staff
👨⚕️
02
Hematologists, oncologists, and clinical specialists
👩⚕️
03
Infection Prevention and Control (IPC) nurses and officers
🦹
04
ICU and high-dependency unit staff caring for immunocompromised patients
👨🔬
05
Pharmacy, chemotherapy, and laboratory staff
💊
06
Quality and patient safety teams
🎓
07
Healthcare professionals involved in immunocompromised patient care
Stronger Standards. Safer Care.
Strengthen your IPC practice and contribute to safer healthcare environments.
Programme Certification
Your certificate
Upon successful completion of this programme, you will receive a digital certificate recognising your achievement and the competencies you have acquired throughout the course.
Certificates for TerraLeap programmes are issued and signed by authorised TerraLeap representatives. For programmes delivered in collaboration with universities, institutions, or industry organisations, certificates are jointly issued and co-signed by authorised representatives of both TerraLeap and the respective partner.
Each certificate carries a unique Certificate ID and QR code to enable instant authenticity verification — making it easy to share with employers, licensing bodies, or professional networks as evidence of your learning.
Note on scope. TerraLeap certificates confirm successful completion of the respective programme and recognise your professional development and continuing education. They do not constitute a professional licence or regulatory authorisation unless explicitly stated in the programme description.
TERRALEAP
Certificate ID
TL-2026-AB7K3X9P
Official
Seal
Certificate of Completion
Successfully Completed
Awarded in recognition of academic achievement
This is to certify that
XXXXX
has successfully completed the prescribed course of study, demonstrating commitment, diligence, and proficiency in
Oncology and Immunocompromised Patient IPC
and is hereby awarded this certificate by TerraLeap, recognising the candidate's mastery of the syllabus and successful evaluation.